Johnson & Johnson, which is in the process of completing its $30 billion acquisition of Swiss biotech Actelion, reported on Tuesday quarterly revenue that missed analysts' estimates, hurt by lower demand for its pharmaceutical products.
Continue Reading Below
The diversified healthcare company's sales rose to $17.77 billion in the first quarter from $17.48 billion a year earlier, but came in below analysts' average estimate of $18.04 billion, according to Thomson Reuters I/B/E/S.
Pharmaceutical sales rose 0.8 percent to $8.25 billion, below Barclays estimate of $8.47 billion.
Net earnings in the quarter were $4.42 billion, or $1.61 per share, compared with $4.46 billion, or $1.59 per share, in the year-earlier period.
Excluding items, the company earned $1.83 per share, beating Street expectations of $1.77 per share.
J&J is the first among major pharmaceutical companies to report quarterly results, a month after the Republican attempt to overhaul the U.S. healthcare system spectacularly failed, although a renewed effort is said to be in the works.
The company's shares slipped nearly 1 percent to $124.60 in premarket trading.
(Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto)